$564.24
-6.03(-1.06%)
Mkt Cap $24.7B
$274.70
$592.98
52-Week Range
At a Glance
AI-generatedRevenue breakdown: Tyvaso (36.1%), Tyvaso DPI (23.3%), Nebulized Tyvaso (12.8%).
8-K
United Therapeutics announced positive results from the TETON-1 clinical study of Tyvaso for idiopathic pulmonary fibrosis, meeting its primary endpoint and demonstrating superiority over placebo.$24.7B
Market Cap
$3.1B
Revenue
$1.3B
Net Income
Employees1,305
Fundamentals
How The Business Makes Money
Revenue by Segment
Tyvaso36.1%($9.5B)
Tyvaso DPI23.3%($6.1B)
Nebulized Tyvaso12.8%($3.4B)
Remodulin11.9%($3.1B)
Orenitram9.8%($2.6B)
Unituxin5.1%($1.3B)
Adcirca0.6%($166M)
Product And Service Other0.4%($116M)
Revenue by Geography
US95.6%($20.6B)
Non Us4.4%($939M)
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001082554
ISINUS91307C1027
CUSIP91307C102
Phone301 608 9292
Address1040 Spring Street, Silver Spring, MD, 20910, US
SEC EDGAR